The Role of CDMO in Small Molecules API Manufacturing: Insights from China and the USA
Saturday, 28 September 2024, 07:14
CDMO Outsourcing and API Manufacturing
CDMO outsourcing has significantly influenced pharmaceutical manufacturing, particularly concerning active pharmaceutical ingredients (APIs). In the context of small molecules, challenges arise when relying on manufacturing bases like China and the USA. The complexities of supply chains can often threaten the stability of pharmaceutical supplies.
The Current Landscape
- The USA depends heavily on China for API sourcing.
- Trade policies impact the outsourcing of pharmaceutical manufacturing.
- Regulatory environments differ significantly between the USA and China.
Future Implications
- Shifts in global policies may reshape sourcing strategies.
- Increased emphasis on local manufacturing could lead to a renaissance in pharmaceutical production.
- Stakeholders must adapt to emerging trends to optimize efficiency.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.